# Special Issue

## Nanoparticles as Novel Solutions to Microbial Resistance in Hospital Care

### Message from the Guest Editor

Nosocomial infections, or healthcare-associated infections, are acquired during medical care and are often caused by multidrug-resistant microorganisms like methicillin-resistant and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, carbapenem-resistant Enterobacteriaceae and Acinetobacter, and multidrug-resistant Pseudomonas aeruginosa. These pathogens significantly increase patient mortality.

Metal nanoparticles, particularly silver nanoparticles, show great promise in combating these infections. Silver nanoparticles not only inhibit the growth of resistant microorganisms but also possess unique properties such as high biocompatibility and ease of use in medical applications.

This Special Issue seeks manuscripts exploring the use of metallic nanoparticles to prevent nosocomial infections and advancing our understanding of their mechanisms in inhibiting multidrug-resistant pathogens.

### Guest Editor

Dr. Zdenka Bedlovičová

Department of Chemistry, Biochemistry and Biophysics, University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81 Košice, Slovakia

### Deadline for manuscript submissions

31 January 2026

**Antibiotics**

**an Open Access Journal by MDPI**

**Impact Factor 4.6**
**CiteScore 8.7**
**Indexed in PubMed**

mdpi.com/si/225285

*Antibiotics*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

# Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

# About the Journal

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

MDPI